Tevogen (TVGN) Change in Accured Expenses (2022 - 2026)

Tevogen Bio Holdings (TVGN) has 5 years of Change in Accured Expenses data on file, last reported at -$258417.0 in Q1 2026.

• Quarterly Change in Accured Expenses fell 194.09% year-over-year to -$258417.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$607270.0 (down 254.15% YoY) and the FY2025 annual result came in at -$74203.0, up 89.11% from the prior year.
• Change in Accured Expenses eased to -$258417.0 in Q1 2026, from $376143.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $376143.0 in Q4 2025 to a low of -$800742.0 in Q1 2024.
• A 5-year average of -$85107.2 and a median of -$7451.0 in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses soared 656.88% — and 2024, when it plunged 1405.89%.
• Tracing TVGN's Change in Accured Expenses over 5 years: stood at $38671.0 in 2022, then sank by 474.1% to -$144669.0 in 2023, then soared by 292.66% to $278722.0 in 2024, then jumped by 34.95% to $376143.0 in 2025, then sank by 168.7% to -$258417.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$258417.0 (Q1 2026), $376143.0 (Q4 2025), and -$379140.0 (Q3 2025), per Business Quant data.